
    
      Male or female participants ages 18 years of age and older for whom the treating physician
      had recently prescribed adalimumab were included in this study. Adalimumab was prescribed in
      accordance with the terms of the local marketing authorization with regards to dose,
      population, and indication. There were 5 planned visits during the study: baseline (Visit 1),
      1 month (Visit 2), 3 months (Visit 3), 6 months (Visit 4), and 9 months (Visit 5).
    
  